Syngene signs 10-year biologics manufacturing agreement with leading animal health company, Zoetis

Jul 15, 2022

The agreement is for the manufacture the drug substance for Librela® (bedinvetmab), a first in class monoclonal antibody used for treating osteoarthritis in dogs

Posted by Syngene International Limited

We are delighted to share that Syngene has signed a 10-year agreement with leading animal health company, Zoetis Inc., to manufacture the drug substance for Librela® (bedinvetmab), a first-in-class monoclonal antibody used for treating osteoarthritis in dogs. Launched in Europe, the UK and Switzerland, the product won ‘Best new companion animal product’ by IHS Markit Connect in 2021 for its transformational impact on pain relief for canines suffering from this debilitating condition.

This agreement, initially centred on Librela®, paves the way for development and manufacturing of other molecules in the coming years and is expected to be worth up to US$ 500 Mn to Syngene over 10 years, subject to regulatory approvals and market demand.

Download Attachment

See all Member News